Industry Research Reports
Global Pegfilgrastim Biosimilar Market Insights, Forecast to 2030
Industry: Pharma & Healthcare
Published Date: 2024-04-25
Pages: 91 Pages
Report ld: 3072313
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Pegfilgrastim Biosimilar Market Size(US$)
CAGR 2024-2030
6.8%
Market Size,2030
USD 2,407
Million
Market Snapshot
Source: Secondary research, interviews with experts, and QYResearch analysis
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
The global Pegfilgrastim Biosimilar market is projected to grow from US$ 1622 million in 2024 to US$ 2407 million by 2030, at a Compound Annual Growth Rate (CAGR) of 6.8% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Pegfilgrastim Biosimilar, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Pegfilgrastim Biosimilar, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Pegfilgrastim Biosimilar, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pegfilgrastim Biosimilar sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Pegfilgrastim Biosimilar market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Pegfilgrastim Biosimilar sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novartis, Mylan, Coherus BioSciences, Mundipharma International, Biocon, Intas Pharmaceuticals, Pfizer and Dr Reddy’s Laboratories, etc.
MARKET SEGMENTATION
By Company
- Novartis
- Mylan
- Coherus BioSciences
- Mundipharma International
- Biocon
- Intas Pharmaceuticals
- Pfizer
- Dr Reddy’s Laboratories
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Chemotherapy Treatment
- Transplantation
Segment by Application
- Hospital Pharmacies
- Mail-Order Pharmacies
- Retail Pharmacies
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Pegfilgrastim Biosimilar in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Pegfilgrastim Biosimilar manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pegfilgrastim Biosimilar sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Pegfilgrastim Biosimilar Product Introduction
1.2 Market by Type
1.2.1 Global Pegfilgrastim Biosimilar Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Chemotherapy Treatment
1.2.3 Transplantation
1.3 Market by Application
1.3.1 Global Pegfilgrastim Biosimilar Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Mail-Order Pharmacies
1.3.4 Retail Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Pegfilgrastim Biosimilar Sales Estimates and Forecasts 2019-2030
2.2 Global Pegfilgrastim Biosimilar Revenue by Region
2.2.1 Global Pegfilgrastim Biosimilar Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Pegfilgrastim Biosimilar Revenue by Region (2019-2024)
2.2.3 Global Pegfilgrastim Biosimilar Revenue by Region (2025-2030)
2.2.4 Global Pegfilgrastim Biosimilar Revenue Market Share by Region (2019-2030)
2.3 Global Pegfilgrastim Biosimilar Sales Estimates and Forecasts 2019-2030
2.4 Global Pegfilgrastim Biosimilar Sales by Region
2.4.1 Global Pegfilgrastim Biosimilar Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Pegfilgrastim Biosimilar Sales by Region (2019-2024)
2.4.3 Global Pegfilgrastim Biosimilar Sales by Region (2025-2030)
2.4.4 Global Pegfilgrastim Biosimilar Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Pegfilgrastim Biosimilar Sales by Manufacturers
3.1.1 Global Pegfilgrastim Biosimilar Sales by Manufacturers (2019-2024)
3.1.2 Global Pegfilgrastim Biosimilar Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Pegfilgrastim Biosimilar in 2023
3.2 Global Pegfilgrastim Biosimilar Revenue by Manufacturers
3.2.1 Global Pegfilgrastim Biosimilar Revenue by Manufacturers (2019-2024)
3.2.2 Global Pegfilgrastim Biosimilar Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Pegfilgrastim Biosimilar Revenue in 2023
3.3 Global Key Players of Pegfilgrastim Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Pegfilgrastim Biosimilar Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Pegfilgrastim Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Pegfilgrastim Biosimilar, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Pegfilgrastim Biosimilar, Product Offered and Application
3.8 Global Key Manufacturers of Pegfilgrastim Biosimilar, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Pegfilgrastim Biosimilar Sales by Type
4.1.1 Global Pegfilgrastim Biosimilar Historical Sales by Type (2019-2024)
4.1.2 Global Pegfilgrastim Biosimilar Forecasted Sales by Type (2025-2030)
4.1.3 Global Pegfilgrastim Biosimilar Sales Market Share by Type (2019-2030)
4.2 Global Pegfilgrastim Biosimilar Revenue by Type
4.2.1 Global Pegfilgrastim Biosimilar Historical Revenue by Type (2019-2024)
4.2.2 Global Pegfilgrastim Biosimilar Forecasted Revenue by Type (2025-2030)
4.2.3 Global Pegfilgrastim Biosimilar Revenue Market Share by Type (2019-2030)
4.3 Global Pegfilgrastim Biosimilar Price by Type
4.3.1 Global Pegfilgrastim Biosimilar Price by Type (2019-2024)
4.3.2 Global Pegfilgrastim Biosimilar Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Pegfilgrastim Biosimilar Sales by Application
5.1.1 Global Pegfilgrastim Biosimilar Historical Sales by Application (2019-2024)
5.1.2 Global Pegfilgrastim Biosimilar Forecasted Sales by Application (2025-2030)
5.1.3 Global Pegfilgrastim Biosimilar Sales Market Share by Application (2019-2030)
5.2 Global Pegfilgrastim Biosimilar Revenue by Application
5.2.1 Global Pegfilgrastim Biosimilar Historical Revenue by Application (2019-2024)
5.2.2 Global Pegfilgrastim Biosimilar Forecasted Revenue by Application (2025-2030)
5.2.3 Global Pegfilgrastim Biosimilar Revenue Market Share by Application (2019-2030)
5.3 Global Pegfilgrastim Biosimilar Price by Application
5.3.1 Global Pegfilgrastim Biosimilar Price by Application (2019-2024)
5.3.2 Global Pegfilgrastim Biosimilar Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Pegfilgrastim Biosimilar Market Size by Type
6.1.1 US & Canada Pegfilgrastim Biosimilar Sales by Type (2019-2030)
6.1.2 US & Canada Pegfilgrastim Biosimilar Revenue by Type (2019-2030)
6.2 US & Canada Pegfilgrastim Biosimilar Market Size by Application
6.2.1 US & Canada Pegfilgrastim Biosimilar Sales by Application (2019-2030)
6.2.2 US & Canada Pegfilgrastim Biosimilar Revenue by Application (2019-2030)
6.3 US & Canada Pegfilgrastim Biosimilar Market Size by Country
6.3.1 US & Canada Pegfilgrastim Biosimilar Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Pegfilgrastim Biosimilar Sales by Country (2019-2030)
6.3.3 US & Canada Pegfilgrastim Biosimilar Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Pegfilgrastim Biosimilar Market Size by Type
7.1.1 Europe Pegfilgrastim Biosimilar Sales by Type (2019-2030)
7.1.2 Europe Pegfilgrastim Biosimilar Revenue by Type (2019-2030)
7.2 Europe Pegfilgrastim Biosimilar Market Size by Application
7.2.1 Europe Pegfilgrastim Biosimilar Sales by Application (2019-2030)
7.2.2 Europe Pegfilgrastim Biosimilar Revenue by Application (2019-2030)
7.3 Europe Pegfilgrastim Biosimilar Market Size by Country
7.3.1 Europe Pegfilgrastim Biosimilar Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Pegfilgrastim Biosimilar Sales by Country (2019-2030)
7.3.3 Europe Pegfilgrastim Biosimilar Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Pegfilgrastim Biosimilar Market Size
8.1.1 China Pegfilgrastim Biosimilar Sales (2019-2030)
8.1.2 China Pegfilgrastim Biosimilar Revenue (2019-2030)
8.2 China Pegfilgrastim Biosimilar Market Size by Application
8.2.1 China Pegfilgrastim Biosimilar Sales by Application (2019-2030)
8.2.2 China Pegfilgrastim Biosimilar Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Pegfilgrastim Biosimilar Market Size by Type
9.1.1 Asia Pegfilgrastim Biosimilar Sales by Type (2019-2030)
9.1.2 Asia Pegfilgrastim Biosimilar Revenue by Type (2019-2030)
9.2 Asia Pegfilgrastim Biosimilar Market Size by Application
9.2.1 Asia Pegfilgrastim Biosimilar Sales by Application (2019-2030)
9.2.2 Asia Pegfilgrastim Biosimilar Revenue by Application (2019-2030)
9.3 Asia Pegfilgrastim Biosimilar Sales by Region
9.3.1 Asia Pegfilgrastim Biosimilar Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Pegfilgrastim Biosimilar Revenue by Region (2019-2030)
9.3.3 Asia Pegfilgrastim Biosimilar Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Pegfilgrastim Biosimilar Market Size by Type
10.1.1 Middle East, Africa and Latin America Pegfilgrastim Biosimilar Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Pegfilgrastim Biosimilar Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Pegfilgrastim Biosimilar Market Size by Application
10.2.1 Middle East, Africa and Latin America Pegfilgrastim Biosimilar Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Pegfilgrastim Biosimilar Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Pegfilgrastim Biosimilar Sales by Country
10.3.1 Middle East, Africa and Latin America Pegfilgrastim Biosimilar Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Pegfilgrastim Biosimilar Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Pegfilgrastim Biosimilar Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Overview
11.1.3 Novartis Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Novartis Pegfilgrastim Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novartis Recent Developments
11.2 Mylan
11.2.1 Mylan Company Information
11.2.2 Mylan Overview
11.2.3 Mylan Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Mylan Pegfilgrastim Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Mylan Recent Developments
11.3 Coherus BioSciences
11.3.1 Coherus BioSciences Company Information
11.3.2 Coherus BioSciences Overview
11.3.3 Coherus BioSciences Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Coherus BioSciences Pegfilgrastim Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Coherus BioSciences Recent Developments
11.4 Mundipharma International
11.4.1 Mundipharma International Company Information
11.4.2 Mundipharma International Overview
11.4.3 Mundipharma International Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Mundipharma International Pegfilgrastim Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Mundipharma International Recent Developments
11.5 Biocon
11.5.1 Biocon Company Information
11.5.2 Biocon Overview
11.5.3 Biocon Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Biocon Pegfilgrastim Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Biocon Recent Developments
11.6 Intas Pharmaceuticals
11.6.1 Intas Pharmaceuticals Company Information
11.6.2 Intas Pharmaceuticals Overview
11.6.3 Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Intas Pharmaceuticals Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Overview
11.7.3 Pfizer Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Pfizer Pegfilgrastim Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Pfizer Recent Developments
11.8 Dr Reddy’s Laboratories
11.8.1 Dr Reddy’s Laboratories Company Information
11.8.2 Dr Reddy’s Laboratories Overview
11.8.3 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Dr Reddy’s Laboratories Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Pegfilgrastim Biosimilar Industry Chain Analysis
12.2 Pegfilgrastim Biosimilar Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pegfilgrastim Biosimilar Production Mode & Process
12.4 Pegfilgrastim Biosimilar Sales and Marketing
12.4.1 Pegfilgrastim Biosimilar Sales Channels
12.4.2 Pegfilgrastim Biosimilar Distributors
12.5 Pegfilgrastim Biosimilar Customers
13 Market Dynamics
13.1 Pegfilgrastim Biosimilar Industry Trends
13.2 Pegfilgrastim Biosimilar Market Drivers
13.3 Pegfilgrastim Biosimilar Market Challenges
13.4 Pegfilgrastim Biosimilar Market Restraints
14 Key Findings in The Global Pegfilgrastim Biosimilar Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1827 million in 2025 and is projected to reach US$ 2877 million, growing at a CAGR of 6.8% from 2026 to 2032.
Published Date: 2026-07-09
Pages: 135
USD 3950.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2026
The global Pegfilgrastim Biosimilar market was valued at US$ 1827 million in 2025 and is anticipated to reach US$ 2877 million by 2032, at a CAGR of 6.8% from 2026 to 2032.
Published Date: 2026-04-21
Pages: 108
USD 2900.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Pegfilgrastim Biosimilar market is projected to grow from US$ 1721 million in 2024 to US$ 2711 million by 2031, at a CAGR of 6.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-10-25
Pages: 149
USD 4900.00
(Single User License)
Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 106
USD 3950.00
(Single User License)
Global Pegfilgrastim Biosimilar Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Pegfilgrastim Biosimilar market size was US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 77
USD 4250.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2025
The global market for Pegfilgrastim Biosimilar was valued at US$ 1721 million in the year 2024 and is projected to reach a revised size of US$ 2711 million by 2031, growing at a CAGR of 6.8% during the forecast period.
Published Date: 2025-02-21
Pages: 82
USD 2900.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2024
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published Date: 2024-02-07
Pages: 82
USD 2900.00
(Single User License)
Pegfilgrastim Biosimilar - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published Date: 2024-01-11
Pages: 101
USD 3950.00
(Single User License)
Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1827 million in 2025 and is projected to reach US$ 2877 million, growing at a CAGR of 6.8% from 2026 to 2032.
Published: 2026-07-09
Pages: 135
USD 3950.00 (Single User License)Global Pegfilgrastim Biosimilar Market Research Report 2026
The global Pegfilgrastim Biosimilar market was valued at US$ 1827 million in 2025 and is anticipated to reach US$ 2877 million by 2032, at a CAGR of 6.8% from 2026 to 2032.
Published: 2026-04-21
Pages: 108
USD 2900.00 (Single User License)Global Pegfilgrastim Biosimilar Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Pegfilgrastim Biosimilar market is projected to grow from US$ 1721 million in 2024 to US$ 2711 million by 2031, at a CAGR of 6.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-10-25
Pages: 149
USD 4900.00 (Single User License)Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 106
USD 3950.00 (Single User License)Global Pegfilgrastim Biosimilar Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Pegfilgrastim Biosimilar market size was US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 77
USD 4250.00 (Single User License)Global Pegfilgrastim Biosimilar Market Research Report 2025
The global market for Pegfilgrastim Biosimilar was valued at US$ 1721 million in the year 2024 and is projected to reach a revised size of US$ 2711 million by 2031, growing at a CAGR of 6.8% during the forecast period.
Published: 2025-02-21
Pages: 82
USD 2900.00 (Single User License)Global Pegfilgrastim Biosimilar Market Research Report 2024
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published: 2024-02-07
Pages: 82
USD 2900.00 (Single User License)Pegfilgrastim Biosimilar - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published: 2024-01-11
Pages: 101
USD 3950.00 (Single User License)
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now